Use of port-a-cath in cancer patients: a single-center experience

Journal of Infection in Developing Countries

Volumn 8, Issue 11, 2014, Pages 1476-1482

  D’Souza, Philomena Charlotte ^a   Kumar, Shiyam ^a   Kakaria, Annupam ^a   Al Sukaiti, Rashid ^a   Zahid, Khawaja Farhan ^a   Furrukh, Muhammad ^a   Burney, Ikram A ^a   Al Moundhri, Mansour S ^b  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^b SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Cancer; Chemotherapy; Infection; Oman; Port a cath

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METICILLIN; OXALIPLATIN; PREDNISOLONE; RITUXIMAB; TRASTUZUMAB; VANCOMYCIN; VINCRISTINE;

ADJUVANT THERAPY; ANTIBIOTIC SENSITIVITY; ANTICOAGULANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CATHETER BLOCKAGE; CATHETER FRACTURE; CATHETER THROMBOSIS; COLON CANCER; COLORECTAL CANCER; FEMALE; GENDER; HODGKIN DISEASE; HUMAN; IMPLANTABLE PORT SYSTEM; INFECTION; INTERNAL JUGULAR VEIN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; NEOPLASM; RETROSPECTIVE STUDY; SKIN DISEASE; SOLID TUMOR; STAPHYLOCOCCUS AUREUS; STOMACH CANCER; THROMBOSIS; ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; INDWELLING CATHETER; MIDDLE AGED; NEOPLASMS; OMAN; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OMAN; RETROSPECTIVE STUDIES; THROMBOSIS; VASCULAR ACCESS DEVICES; YOUNG ADULT;

EID: 84924263884     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.4155     Document Type: Article

References (25)

1. Ignatov A, Hoffman O, Smith B, Fahlke J, Peters B, Bischoff J, Costa SD (2009) An 11-year retrospective study of totally implanted central venous access ports: Complications and patient satisfaction. Eur J Surg Oncol 35: 241-246. doi: 10.1016/j.ejso.2008.01.020.
2. Khoury MD, Lloyd LR, Burrows J, Berg R, Yap J (1985) A totally implanted venous access system for the delivery of chemotherapy. Cancer 56: 1231-1234.
3. Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, Della Vigna P, Rotmensz N, Radice D, Zampino MG, Fazio N, de Braud F, Andreoni B, Goldhirsch A (2009) Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 20: 935-940. doi: 10.1093/annonc/mdn701.
4. Garajová I, Nepoti G, Paragona M, Brandi G, Biasco G (2013) Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation. Eur J Cancer Care (Engl) 22: 125-132. doi: 10.1111/ecc.12008.
5. Capalbo E, Peli M, Lovisatti M, Cosentino M, Ticha V, Cariati M, Cornalba G (2013) Placement of port-a-cath through the right internal jugular vein under ultrasound guidance. Radiol Med 118: 608-615. doi: 10.1007/s11547-012-0894-6.
6. Subramaniam A, Kim KH, Bryant SA, Kimball KJ, Huh WK, Straughn JM, Estes JM, Alvarez RD (2011) Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies. Gynecol Oncol 123: 54-57. doi: 10.1016/j.ygyno.2011.06.012.
7. Raaf JH (1985) Results from use of 826 vascular access devices in cancer patients. Cancer 55: 1312-1321.
8. Walser EM (2012) Venous access ports: indications, implantation technique, follow-up, and complications. Cardiovasc Intervent Radiol 35: 751-764. doi: 10.1007/s00270-011-0271-2.
9. Sawayama H, Hayashi N, Watanabe M, Takamori H, Beppu T, Baba H (2012) The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients. Surg Today 42: 29-34. doi: 10.1007/s00595-011-0016-5.
10. Sticca RP, Dewing BD, Harris JD (2009) Outcomes of surgical and radiologic placed implantable central venous access ports. Am J Surg 198: 829-833. doi: 10.1016/j.amjsurg.2009.04.031.
11. Burney IA, Khurshaidi N, Akbar MT, Bhatti FN, Siddiqui T, Sophie Z (2001) Complications of in-dwelling venous access devices: a single institution experience. JPMA J Pak Med Assoc 51: 434-437.
12. Kock HJ, Pietsch M, Krause U, Wilke H, Eigler FW (1998) Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg 22: 12-16.
13. Chang YF, Lo AC, Tsai CH, Lee PY, Sun S, Chang TH, Chen CC, Chang YS, Chen JR (2013) Higher complication risk of totally implantable venous access port systems in patients with advanced cancer-a single institution retrospective analysis. Palliat Med 27: 185-191. doi: 10.1177/0269216311428777.
14. Poorter RL, Lauw FN, Bemelman WA, Bakker PJ, Taat CW, Veenhof CH (1996) Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. Eur J Cancer 32A: 2262-2266.
15. Ohno H, Mizumoto C, Otsuki Y, Oguma S, Yoshida Y (2010) The duration of functioning of a subcutaneous implantable port for the treatment of hematological tumors: a single institution-based study. Int J Clin Oncol 15: 172-178. doi: 10.1007/s10147-010-0039-8.
16. Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A, Nolè F, Andreoni B (1998) Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol 9: 767-773.
17. Beckers MMJ, Ruven HJT, Seldenrijk CA, Prins MH, Biesma DH (2010) Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. Thromb Res 125: 318-321. doi: 10.1016/j.thromres.2009.06.008.
18. Alkindi S, Matwani S, Al-Maawali A, Al-Maskari B, Pathare A (2012) Complications of PORT-A-CATH® in patients with sickle cell disease. J Infect Public Health 5: 57-62. doi: 10.1016/j.jiph.2011.10.004.
19. Brincker H, Saeter G (1986) Fifty-five patient years’ experience with a totally implanted system for intravenous chemotherapy. Cancer 57: 112-1129. doi: 10.1002/1097-0142(19860315)57:6<1124::AID-CNCR2820570611>3.0.CO;2-D.
20. Gallieni M, Pittiruti M, Biffi R (2008) Vascular access in oncology patients. CA Cancer J Clin 58: 323-346. doi: 10.3322/CA.2008.0015.
21. Bonczek R, Nurse BA (2012) Management of Port-a-Cath devices in long-term acute care hospitals. Rehabil Nurs 37: 307-311. doi: 10.1002/rnj.57.
22. Karthaus M, Kretzschmar A, Kröning H, Biakhov M, Irwin D, Marschner N, Slabber C, Fountzilas G, Garin A, Abecasis NG, Baronius W, Steger GG, Südhoff T, Giorgetti C, Reichardt P (2006) Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17: 289-296. doi: 10.1093/annonc/mdj059.
23. Karthaus M (2008) Prophylaxis of catheter-related venous thrombosis in cancer patients. Support Care Cancer 16: 787-790. doi: 10.1007/s00520-007-0374-0.
24. Campisi C, Biffi R, Pittiruti M (2007) Catheter-Related Central Venous Thrombosis: The Development of a Nationwide Consensus Paper in Italy. J Assoc Vasc Access 12: 38-46. doi: 10.2309/java.12-1-10.
25. Niers TMH, Di Nisio M, Klerk CPW, Baarslag HJ, Büller HR, Biemond BJ (2007) Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 5: 1878-1882. doi: 10.1111/j.1538-7836.2007.02660.x.